Following on from the VISION trial (NCT03511664), Karim Fizazi, MD, PhD, Institut Gustave Roussy, Villejuif, France, discusses issues concerning Lu-PSMA-617 deployment, highlighting the salient challenge of treatment accessibility and how this may be addressed through collaboration between key players. Furthermore, Dr. Fizazi provides insight into the future of prostate cancer treatment; new therapies utilizing alternative prostate-specific membrane antigen (PSMA) targeting mechanisms are likely to be developed, such as PSMA bispecific T-cell engagers (BiTEs), as well as therapies against novel targets, such as the androgen receptor (AR). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

свернуть